In terms of therapeutic responses, the results obtained from the HER2CLIMB study demonstrate that the combination of tucatinib with trastuzumab and capecitabine shows higher effectiveness compared to trastuzumab and capecitabine alone in treating individuals diagnosed with HER2-positive breast cancer. Here, ERBB2 is linked to breast cancer.